Adenovirus is a widely used vector for cancer gene therapy because of its high infection efficiency and capacity for transgene expression in both dividing and nondividing cells. However, neutralisation of adenovirus by pre-existing antibodies can lead to inefficient delivery, and the wide tissue distribution of the coxsackie and adenovirus receptor (CAR, the primary receptor for adenovirus type 5) precludes target selectivity. These limitations have largely restricted therapeutic use of adenovirus to local or direct administration. A successful viral gene therapy vector would be protected from neutralising antibodies and exhibit a preferential tropism for target cells. We report here the development of a covalent coating and retargeting strategy using a multivalent hydrophilic polymer based on poly-[N-(2-hydroxypropyl)metha-
Introduction
Recombinant adenoviruses are powerful vectors for gene therapy since they efficiently infect both proliferating and non-proliferating cells. However several factors restrict their usefulness: the widespread distribution of the coxsackie and adenovirus receptor 1 (CAR), while allowing infection of a range of tissues, precludes specific in vivo targeting; most people have been exposed to natural adenovirus infection, which confers long-term immunity and may compromise effective virus delivery; 2,3 even replication-deficient or 'gutless' virus can provoke immune responses, preventing repeated dosing and limiting the duration of therapeutic gene expression. 4, 5 Virus tropism has previously been modified genetically by re-engineering the knob domain of fibre, the virus protein that interacts with CAR, [6] [7] [8] or by applying bispecific molecules that recognise both the knob domain and a cell receptor. [9] [10] [11] We report here a nongenetic strategy to modify the surface of the virion with a multivalent copolymer based on poly-[N-(2-hydroxypropyl) methacrylamide] (pHPMA), a hydrophilic polymer that has been extensively developed as a drug carrier. 12 pHPMA has been evaluated comprehensively in animals for a range of purposes and has been used to deliver crylamide] (pHPMA). Incorporation of targeting ligands such as basic fibroblast growth factor and vascular endothelial growth factor on to the polymer-coated virus produces ligand-mediated, CAR-independent binding and uptake into cells bearing appropriate receptors. Retargeted virus is resistant to antibody neutralisation and can infect receptorpositive target cells selectively in mixed culture, and also in xenografts in vivo. Multivalent polymeric modification of adenovirus is an effective way of changing its tropism and interaction with the immune system. As a non-genetic onestep process, the technology is simple, versatile and should yield vectors with an improved safety profile. Gene Therapy (2001) 8, 341-348.
anticancer anthracyclines in human patients, 13 exhibiting encouraging therapeutic efficacy and good biocompatibility.
In this study we have used a multivalent reactive 16.5 kDa pHPMA-based copolymer to modify the surface of adenoviruses, in order to shield them from recognition by antibodies, to ablate their normal pathways of receptor binding and to permit retargeting following introduction of new ligands. A similar approach has been very successful at masking and retargeting nonviral vectors for gene delivery. 14, 15 The copolymer bears reactive 4-nitrophenoxy groups on pendent diglycyl side chains, at a density of 10 reactive centres (side chains) per 100 monomer units (10 mol%, pHPMA-ONp, Figure 1a ). The ability of polymer modification to ablate normal pathways of viral entry into cells and infection was examined, and new ligands were subsequently introduced chemically to retarget the polymer-coated viruses to infect via specific target-associated receptors. The resistance of retargeted viruses to neutralisation by anti-adenovirus antibodies was characterised, together with their ability to infect target cells selectively in mixed cultures in vitro. Finally the ability of polymer-modified and retargeted viruses to infect human carcinoma cells growing as a peritoneal xenograft in nude mice was demonstrated. The simplicity and generic applicability of this system should enable it to fulfil several key requirements for successful application of gene therapy.
Results
Physicochemical and biological characterisation of polymer-coated adenovirus The pHPMA-ONp copolymer ( Figure 1a ) was reacted with amino groups on the adenovirus surface and the reaction terminated after 12 h by aminolysis of the residual reactive ester groups. Under standard conditions (2 mg polymer plus 10 11 virus particles in 125 l 10% glycerol/PBS pH 7.8) 74% of the free amino groups on the virion surface became substituted (Figure 1b) , with an average 923 ± 69 polymer molecules linked to each virus particle (determined using 14 C-trace labelled pHPMAONp copolymer). Since there are at least 18 000 reactive amino groups on the virus surface, 16 this suggests each polymer is attached via approximately 14 separate linkages. This provides a strong indication of co-operative binding of reactive esters within individual polymer molecules to the virus surface. Co-operative binding means that efficient virus modification can be achieved using reactive esters presented at 1-2 mm on multivalent HPMA copolymers, compared with a requirement for approximately 20 mm when presented as monovalent poly(ethylene glycol) (pEG). 16, 17 The pHPMA-coated virus (pc virus) retained the same gross morphology as untreated virus viewed by TEM, although it stained positively with phosphotungstic acid (Figure 1c) . Analysis of particle size by photon correlation spectroscopy (PCS) showed an average diameter of the unmodified virus of 104.8 ± 0.9 nm (polydispersity 0.02), compared with 127.7 ± 1.5 nm (polydispersity 0.2) for the pc virus. Western blot analysis of pc virus with an antifibre antibody ( Figure 1d) showed that with increasing amount of polymer the intensity of the 62 kDa fibre monomer band progressively decreased, suggesting modified electrophoretic mobility or less efficient recognition by antibody. At high levels of polymer the 62 kDa band disappeared and positive staining was discerned at the top of the gel, indicating a loss of electrophoretic mobility for extensively polymer-modified fibre.
To test whether polymer-coated adenovirus was able to infect cells, the expression of green fluorescent protein (gfp) encoded by an E1-deleted, replication-deficient recombinant Ad5 virus (Adgfp ⌬E1 ) was assessed ( Figure 2 ). A549 human lung carcinoma cells are fully permissive for wild-type adenovirus type 5 (Ad5wt), and support the expression of gfp from E1-deleted virus. When infected with 10 4 particles Adgfp ⌬E1 /cell, A549 cells showed bright fluorescence in over 90% of cells at 48 h after infection, while pc-Adgfp ⌬E1 gave no detectable fluorescent signal (Figure 2a) . Measurement of gfp expression in a fluorescence plate reader (Figure 2b ) confirmed that the ability of the virus to infect A549 cells was essentially ablated by the coating procedure. pHPMA-coating also ablated the characteristic Ad5wt cytopathic effect (cpe) in A549 cells, although reaction with monofunctional pEG bearing an equivalent number of reactive esters did not inhibit virus-mediated cpe (not shown).
To see whether polymer-coated virus could bind to and enter cells, virus was labelled with the DNA-intercalating fluorescent dye YOYO-1 (Molecular Probes, Eugene, OR, USA) for use in a flow cytometry assay. Uptake of Ad5wt by A549 cells during 2 h incubation at 37°C was effectively abolished by the presence of the polymer coat 
(i) Uninfected cells; infection with (ii) virus, (iii) pc-virus, (iv) bFGF-pc-virus. (b) A549 were infected as above. At 48 h after infection, the medium was removed, the cells lysed with 100 l Triton X-100 (0.2% in H 2 O), and gfp fluorescence measured at ex 485 nm and em 538 nm in a Fluoroskan fluorescence plate reader (Labsystems, Cambridge UK). The bars are coded as follows: (i) uninfected cells, (ii) virus, (iii) pc virus, (iv) bFGF-pc-virus, (v) VEGF-pc-virus. (c) A549 cells were trypsinised, aliquoted at 10 5 cells/500 l DMEM/10% FCS and incubated in sterile Eppendorf tubes on a rotary mixer for 2 h at 37°C, before addition of 8.6 × 10 9 particles Ad5wt or pc-Ad5wt labelled with YOYO-1. Cell suspensions were incubated with mixing (2 h, 37°C), centrifuged (2 min, 900 g), washed in PBS and fixed in 500 l 4% paraformaldehyde pH7.4 (5 min). Association of YOYO-1 labelled virus with cells was measured using a Coulter EPIC XL flow cytometer with an argon laser set for ex 488 nm and em 520 nm. Fluorescence profile for (i) control cells (thin line) and cells infected with virus (thick line); (ii) pc virus; (iii) bFGF-pc-virus.
Gene Therapy (Figure 2c ). The same assay, conducted at 4°C to inhibit internalisation, confirmed that pc virus did not bind to cells (not shown).
Retargeting polymer-coated adenovirus to alternative receptors The possibility of directing adenovirus to new receptors by linkage of ligands to the polymer coat was investigated. Adenovirus enters cells and delivers its DNA to the nucleus by a highly regulated pathway involving interaction with integrins, internalisation into endosomes, activation of the virus protease and release of modified virus particles into the cytoplasm, traffic to the nuclear pore and translocation of active genomes to specific sites in the nuclear matrix. [18] [19] [20] [21] [22] It was therefore not obvious whether a virus particle extensively coated with a stable polymer would be capable of efficient gene delivery, even if the particle could be retargeted to a novel receptor on the cell surface. To test the feasibility of retargeting, bFGF and VEGF 165 were selected as ligands. bFGF was chosen because it has previously been used successfully to retarget adenovirus, 11, 23 while VEGF 165 is known to enter the endosomal pathway following receptor-binding 24 and could be used to confer selectivity towards endothelial cells. Targeting ligands were incorporated on to the reactive ester groups remaining on the surface of the pc virus after 2 h of virus-polymer interaction (see Materials and methods). The ability of bFGF to mediate uptake of pc viruses into bFGF receptor-positive cells was determined by flow cytometry of A549 cells following 2 h incubation at 37°C with bFGF-retargeted pc-Ad5wt prelabelled with YOYO-1. Under conditions where uptake of nontargeted pc-Ad5wt was blocked, bFGF-retargeted pc-Ad5wt demonstrated cellular uptake levels similar to those of unmodified YOYO-1-labelled Ad5wt (Figure 2c) .
The ability of bFGF-and VEGF-retargeted pc viruses (bFGF-pc-virus and VEGF-pc-virus, respectively) to express transgenes was evaluated using four different cell types. In A549 cells, where pc-Adgfp ⌬E1 is inactive, bFGF-pc-Adgfp ⌬E1 produced high gfp expression, comparable to that mediated by the unmodified Adgfp ⌬E1 (Figure 2 ). In contrast VEGF-pc-Adgfp ⌬E1 showed limited gfp expression, consistent with the absence of VEGF receptors (Figure 2b ). In murine A9 cells, which contain FGF receptors but lack CAR and are not permissive for fibre-mediated infection, 25 only low levels of gfp were expressed by Adgfp ⌬E1 and pc-Adgfp ⌬E1 ( Figure 3a) ; retargeting with bFGF produced 24-fold greater gfp, while retargeting with VEGF was not productive. A9-21 cells, which contain human chromosome 21 and express human CAR, 25 supported Adgfp ⌬E1 infection (Figure 3b ). pc Virus was not infective, and gfp expression could be restored using bFGF-pc-Adgfp ⌬E1 , but not VEGF-pcAdgfp ⌬E1 . In contrast, in primary human umbilical endothelial (HUVE) cells, which have low levels of CAR but express receptors for both VEGF and bFGF, efficient gfp expression was accomplished using both ligands (Figure 3d ). In these cells, retargeting the pc virus with VEGF achieved significantly more gfp expression than unmodified Adgfp ⌬E1 or pc virus retargeted with bFGF.
Ligand specificity of infection was confirmed by incubating HUVE cells with bFGF-pc-Adgfp ⌬E1 or VEGF-pcAdgfp ⌬E1 in the presence of antibody to bFGF or VEGF; gfp expression was decreased by 79.1% or 65.6%, respectively (Figure 3d ). The ability of excess ligand to antagonise infection was shown by infecting A9 cells with bFGFretargeted pc virus in the presence of 50 g/ml free bFGF, achieving over 85% inhibition (Figure 3c ). The presence of free bFGF had no significant effect on the low activity of Adgfp ⌬E1 in A9 cells. Furthermore, infection with Adgfp ⌬E could be inhibited in A549 cells by addition of soluble Ad5 fibre knob domain protein 6 to the culture medium, although this had no effect on infectivity of bFGF-pc-Adgfp ⌬E1 (Figure 3e) .
The possibility for cell selective receptor-mediated infection was demonstrated by exposing co-cultures of CAR expressing SUIT2 human pancreatic carcinoma cells and VEGF receptor expressing HUVE cells to infection by Adgfp ⌬E1 or VEGF-pc-Adgfp ⌬E1 (Figure 4) . In co-culture, as in single culture, the unmodified virus showed efficient gfp expression in SUIT2 cells and relatively low infectivity in HUVE cells. In contrast, virus retargeted with VEGF showed significantly enhanced gfp expression in HUVE cells, and very limited infection of SUIT2, suggesting that selective infection in complex environments should be feasible.
Resistance of polymer-coated adenovirus to binding and neutralisation by anti-adenovirus antibodies
The availability of virion surface epitopes to antibodies was tested in a capture ELISA assay, 3 where anti-adenovirus antibodies remaining free in solution after incubation with virus are detected on a virus-coated ELISA plate. Using 3.45 × 10 9 virus particles (1 g protein), Ad5wt reduced the titre of free rabbit anti-adenovirus antibodies to background level, while pc-Ad5wt effected no detectable reduction (Figure 5a ). Under the conditions used, 30 ng of virus protein is the saturating dose required to interact with all the antibody and reduce the signal to background level (not shown), yet a 30-fold excess of pc virus was unable to achieve any significant reduction in the free antibody titre, showing that the polymer-coating procedure is a very effective shield against antibody recognition.
The ability of retargeted pc viruses to infect in the presence of neutralising antibody was tested by incubating modified virus in the presence of ascitic fluid known to contain anti-adenovirus neutralising antibodies, isolated from a patient with ovarian carcinoma. 3 Retargeted pc virus was less susceptible to inhibition of infection than the unmodified virus. Figure 5b shows that bFGF-pcAdgfp ⌬E1 is 10-fold more resistant to neutralisation than Adgfp ⌬E1 .
Infection of human carcinoma cells in vivo
In order to evaluate the performance of retargeted adenovirus in the more complex in vivo environment, nude mice bearing intraperitoneal xenografts of SUIT2 cells were administered Adgfp ⌬E1 , pc-Adgfp ⌬E1 or retargeted bFGF-pc-Adgfp ⌬E1 . Peritoneal cells recovered after 48 h showed high levels of gfp expression in animals treated with unmodified Adgfp ⌬E1 , and none in animals treated with non-targeted pc-Adgfp ⌬E1 (Figures 6). In contrast, bFGF-pc-Adgfp ⌬E1 gave high levels of gfp expression (Figure 6c ), indicating that efficient targeting and infection is possible in vivo using this retargeting strategy. Similar experiments were performed using the ␤-galactosidase-expressing adenovirus Ad␤-gal ⌬E1 to enable precise determination of transgene expression by luminometry of peritoneal cell lysates. Comparing levels of transgene expression in the whole cell population shows that pc-Ad␤-gal ⌬E1 produced at least 100-fold less ␤-galactosidase than the unmodified parent virus, while bFGF-pc-Ad␤gal ⌬E1 achieved at least 10-fold more (Figure 6d) . In order to compare the levels of infection in human and murine cells, tumour cells were separated from murine cells by FACS on the basis of expression of carcinoembryonic antigen (CEA) using a murine monoclonal antibody; all detectable ␤-galactosidase expression was associated with the human tumour cells and nothing was found in CEA-negative murine cells (not shown). bFGF does not normally show selectivity for tumour cells, however, and experiments are underway to evaluate the selectivity and usefulness of infection targeted via tumour-restricted receptors.
Discussion
Modification of the surface of adenovirus using multivalent reactive pHPMA ablates CAR binding, shields the virus from neutralising antibodies, and permits incorporation of new ligands for virus retargeting. The striking finding that adenovirus retargeted to bFGF and VEGF receptors can infect cells efficiently following receptorbinding, despite extensive covalent surface modification with a nonbiodegradable polymer, has important impli- cations for the development of gene therapy vectors. The possibility to retarget adenoviruses to selected receptors provides the opportunity to refine their tissue tropism and their distribution kinetics in vivo, and the avoidance of CAR-mediated infection of nontarget tissues should permit the use of lower viral doses. Evasion of neutralisation by pre-existing anti-adenovirus antibodies should also enable use of decreased doses. This is expected to decrease the toxicity associated with adenovirus gene therapy and could significantly improve the efficacy and safety of the approach.
Figure 3 Infectivity of retargeted virus. A9, A9-21, A549 and HUVE cells were seeded into 96-well plates (10 4 cells per well), and infected after 24 h with 10 4 particles per cell Adgfp ⌬E1 , pc-Adgfp ⌬E1 , or pc-Adgfp ⌬E1 retargeted with bFGF or VEGF, in phenol red-free DMEM/2% FCS (A549, A9, A9-21) or M199/20% FCS (HUVE). At 48 h after infection, fluorescence was measured as before (Figure 2b
There have been previous studies using monovalent pEG to modify the surface of adenovirus, although a major objective was to develop pEGylated virus that maintains CAR-mediated infection. 16, 26 We set out to ablate normal pathways of infection completely, using
Gene Therapy multivalent polymer in order to maximise binding to the virus surface. This approach simultaneously permits easy linkage of targeting ligand to the polymer-coated viruses, without the need for heterobifunctional chemistry. 17 pHPMA is an attractive polymer for this purpose since it is not fusogenic (unlike pEG), hence allowing development of stealth-like virus without enhanced infection through nonspecific membrane activity. 26, 27 Finally, virus modification with multivalent polymers not only permits incorporation of a range of targeting molecules (eg tumour-associated surface antigens), but also of other biological effectors (eg enzymes), to enhance properties such as tissue penetration, as well as programming tropism. 
Figure 4 Selective infectivity by retargeted virus. SUIT2 and HUVE cells were grown separately, trypsinised and resuspended in DMEM/2% FCS or M199/20% FCS, respectively, at a density of 5 × 10 4 cells/ml. Cells were mixed in equal numbers and, after 2 h recovery at 37°C, virus was added (10 4 particles per cell) and incubated for a further 1.5 h before plating on to gelatin-coated 24-well plates. Phase contrast and fluorescence images were recorded at 48 h after infection (a and b) Adgfp ⌬E1 (c and d) VEGF-pc-Adgfp

Materials and methods
Cells and viruses A549 human lung carcinoma cells, 293 adenovirus transformed human embryo kidney cells, SUIT2 human pancreatic carcinoma cells and murine A9 fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% foetal calf serum (FCS) and 2 mm glutamine. The CAR-expressing subline A9-21 25 was maintained in the same medium with 400 g/ml G418. HUVE cells (isolated from cords donated to the Birmingham Women's Hospital) were kept in medium M199 plus 20% FCS and used before passage 3. Ad5wt was propagated in A549 cells. Adgfp ⌬E1 and Ad␤-gal ⌬E1 are E1, E3 deleted Ad5 recombinant viruses expressing green fluorescent protein (gfp) or ␤-galactosidase (␤-gal) under control of the CMV promoter. They were grown in 293 cells, using DMEM with 2% FCS. Virus was purified on CsCl gradients and particle counts determined using the equation 1 mg/ml virus protein = 3.45 × 10 12 particles/ml. 28 Infectivity was measured by plaque assay in 293 cells; particle:infectivity ratios of 10-50 were obtained for all virus stocks.
Virus modification and characterisation
A random copolymer (pHPMA-ONp) containing N-(2-hydroxypropyl)methacrylamide (90 mol%) and methacryloyl-Gly-Gly-4-nitrophenoxy ester (10 mol%) with number average molecular weight 16 500 was prepared and characterised as described. 29 The structure is shown in Figure 1a . For polymer modification of virus, 25 l pHPMA-ONp (10 mg/ml in H 2 O) was added to 10 11 particles Ad5wt or Adgfp ⌬E1 in 100 l 10% glycerol/PBS pH 7.8, and incubated at 4°C for 12 h to form polymer-coated adenovirus (pc-Ad5wt or pc-Adgfp ⌬E1 ). The reaction was terminated by addition of aminoethanol (final concentration 0.1% v/v) to effect aminolysis of the remaining reactive ester groups, and the material was used without further purification. The extent of modification was assessed using fluorescamine to estimate the number of residual free amino groups on the virion surface; 30 the final aminolysis step was omitted, fluorescamine (125 l, 100 g/ml in acetone) added to 5 l aliquots (3.45 × 10 9 virus particles) and fluorescence measured after 10 min at ex 392 nm and em 480 nm using 10 nm slit width in an LS-50B fluorimeter (Perkin-Elmer, Beaconsfield, UK). To determine the amount of polymer incorporated on to the virus, the pHPMA-ONp was radiolabelled by partial reaction with 14 C-aminoethanol (1.0 mol%) before reaction with the virus.
For linkage of targeting agent, following an initial 2 h incubation of virus with pHPMA-ONp, bFGF 165 or VEGF 165 (gifts from Selective Genetics, San Diego, CA, USA, and AstraZeneca, Macclesfield, UK, respectively) was added to a final concentration of 80 g/ml, and incubation continued for a further 10 h, before termination of the reaction with aminoethanol. In characterisation studies the modified virus was purified from free polymer and free targeting agents using SizeSep 400 Spun Columns (Pharmacia, Uppsala, Sweden). Recovery of targeting agent, polymer and virus were determined by ELISA, radioactive content and infectivity or YOYO-1 fluorescence, respectively. The extent of FGF binding was assessed using an ELISA kit (DAKO, Ely, UK). Spun column purified retargeted virus (1-100 ng protein in 100 l PBS) was captured on a 96-well plate bearing monoclonal anti-human FGF (2 h, room temperature) and virion bound FGF detected with a peroxidase conjugated secondary antibody. To label virus DNA with fluorescent dye, Ad5wt (2.5 × 10 11 particles/100 l) was incubated on ice for 1 h with the cyanine dimer nucleic acid stain YOYO-1 (1 l, 100 nm; Molecular Probes) and dialysed against PBS/10% glycerol. YOYO-1 labelled virus was coated with pHPMA-ONp as above.
Particle size after virus modification was measured by photon correlation spectroscopy using a Zetasizer 1000HS (Malvern, Instruments, Malvern UK) equipped with a 50 mW internal argon laser. Measurements were performed at 25°C in PBS/glycerol (10%) with Refractive Index set to 1.33 and sampling time, analysis and method set to automatic. Results are each the average of six replicates, each involving 10 separate analyses.
Western blot analysis was used to detect adenovirus fibre after polymer modification: Ad5wt virus (6.9 × 10 9 particles, 2 g protein) was reacted with pHPMA-Onp (0-2 mg/ml), and the virion proteins resolved by SDS-PAGE (10% Protogel, National Diagnostics, Hull, UK). The proteins were transferred by semi-dry electroblotting to nitrocellulose membrane (Gelman Sciences, Northampton, UK), blocked in 5% non-fat dried milk/0.1%Tween/PBS for 90 min at room temperature, and probed with a guinea pig anti-fibre antibody (10 −3 dilution in 0.1% Tween/PBS, 90 min, 22°C), followed by an anti-guinea pig Ig peroxidase conjugate at 10
Gene Therapy dilution in the same buffer (Sigma Chemical, Poole, UK). The membrane was incubated with ECL reagents (Amersham plc, Amersham, UK) for 30 s, and exposed to X-OMAT AR film (Kodak) for 30 s.
Synthesis and purification of adenovirus knob domain protein Adenovirus type 5 knob domain (amino acids 387-581) was cloned in the pET3a vector (Novagen, Madison, WI, USA) and propagated in BL21pLysS bacteria; protein synthesis was induced by overnight incubation at 25°C in the presence of 1 mm IPTG, and the protein purified by MonoQ column chromatography, and eluted at 25.6 mm NaCl, as described. For FACS analysis, cells were trypsinised, aliquoted at 10 5 cells per 500 l DMEM/10% FCS and incubated in sterile Eppendorf tubes on a rotary mixer for 2 h at 37°C to allow regeneration of receptors, before addition of 8.6 × 10 9 particles Ad5wt or pc-Ad5wt labelled with YOYO-1. Cell suspensions were incubated with mixing (2 h, 37°C), centrifuged (2 min, 900 g), washed in PBS and fixed in 500 l 4% paraformaldehyde pH 7.4 (5 min). Association of YOYO-1 labelled virus with cells was measured using a Coulter EPIC XL flow cytometer with an argon laser set for ex 488 nm and em 520 nm.
An ELISA assay was used to measure antibody binding to polymer modified virus. One hundred microlitres of Ad5wt or pc virus (1 g protein in 0.1% Tween/PBS) was incubated with an equal volume of a rabbit anti-adenovirus serum (final dilution 1:3200) for 2 h at 37°C. Residual unbound antibody was captured on an ELISA plate coated with heat-inactivated Ad5wt virus (30 min, 56°C) and detected with goat anti-rabbit peroxidase conjugate, as previously described.
